Biggest Companies in the Gene Knockdown Stable Cell Line Service Market
- GenScript
- Thermo Fisher Scientific
- PerkinElmer / Horizon Discovery (Revvity)
- Cyagen Biosciences
- Charles River Laboratories
- WuXi AppTec
- VectorBuilder
- OriGene Technologies
- Cellecta
- Creative Biolabs / Creative Biogene
- GeneCopoeia
- Altogen Labs
- BPS Bioscience
- Ubigene
- Sino Biological
- Vigene Biosciences
- Creative Diagnostics
- Geneticist / Regional Specialists
- Eurofins / SGS / Large testing groups
- Academic core facilities/niche CROs
Market Growth
The global gene knockdown stable cell line service market size recorded US$ 715 million in 2024, set to grow to US$ 774 million in 2025 and projected to hit nearly US$ 1557 million by 2034, with a CAGR of 8.16% throughout the forecast timeline.
What are the Key trends in the Gene Knockdown Stable Cell Line Service Market in 2024?
Collaborations Between Academic Institutions and Industry: Partnerships enhance innovation, expand access to cutting-edge technologies, and promote the use of stable knockdown cell lines in research.
- In May 2025, ProBioGen partnered with Poland’s Polpharma Biologics to provide CHO.RiGHT cell-line development services, supporting the rapid expansion of its biosimilar pipeline.
Introduction of Advanced Stable Knockdown Cell Lines: New launches of highly efficient and specific knockdown cell lines improve research accuracy and expand applications in drug discovery and functional genomics.
- In April 2025, Thermo Fisher Scientific introduced an advanced integrated platform featuring a high-yield CHO K-1 cell line, cutting IND-filing timelines from 13 to 9 months and enhancing both stability and productivity.
Latest Announcement by Industry Leaders
In October 2024, WuXi Biologics launched WuXia™ RidGS, a high-yield GS-knockout CHO cell platform using ZFN technology for non-antibiotic stable cell line development. The platform ensures high expression, stable productivity, and consistent quality for mAbs and other therapeutic proteins. Dr. Chris Chen, CEO, highlighted that WuXia™ RidGS accelerates therapeutic protein development, speeding market entry and improving global access to high-quality biologics.
Recent Developments in the Gene Knockdown Stable Cell Line Service Market
- In May 2025, AstraZeneca acquired the cell therapy startup EsoBiotec for USD 425 million upfront, enhancing its cell therapy development capabilities.
- In January 2025, BioCina and NovaCina merged to form a global biopharmaceutical leader, combining capabilities from cell line development to commercial-scale production under the unified BioCina brand.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
